UPCC 11522 A Multicenter Phase II Study of Pomalidomide Monotherapy in Kaposi Sarcoma

Age
99 years or below
Gender
All
participants needed
15
Location
1
UPCC 11522 A Multicenter Phase II Study of Pomalidomide Monotherapy in Kaposi Sarcoma

Brief description of study

This phase II trial studies the effect of pomalidomide in treating patients with Kaposi sarcoma. Pomalidomide is a cancer fighting drug that stops the growth of blood vessels, stimulates the immune system, and may kill cancer cells.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Kaposi Sarcoma
  • Age: 99 years or below
  • Gender: All


Updated on 04 Aug 2024. Study ID: 851611
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research